From: DNA methylation mediates the effect of cocaine use on HIV severity
 | Baselinea | Follow-up (time of blood collection)b |
---|---|---|
Sample size | 1435 | 875 |
 Age [mean (sd)] | 48.8 (8.1) | 51.5 (7.7) |
 Sex |  |  |
  Male | 1399 (97.5%) | 861 (98.4%) |
  Female | 36 (2.5%) | 14 (1.6%) |
 Race |  |  |
  Caucasian | 290 (20.2%) | 84 (9.6%) |
  African American | 964 (67.2%) | 726 (83.0%) |
  Others | 181 (12.6%) | 65 (7.4%) |
 Persistent cocaine use status |  |  |
  Persistent cocaine use |  | 265 (30.3%) |
  Non-cocaine use |  | 202 (23.1%) |
 Cocaine use at baseline (%) |  |  |
  Have never tried | 555 (38.7%) |  |
  No use in the last year | 540 (37.6%) |  |
  Less than once a month | 122 (8.5%) |  |
  1–3 times a month | 103 (7.2%) |  |
  1–3 times a week | 39 (2.7%) |  |
  ≥ 4 times a week | 76 (5.3%) |  |
 Cigarette smoking | 762 (53.1%) | 521 (59.5%) |
 VACS index | 30.0 (19.1) |  |
Average VACS index after blood collection [mean (sd)] | Â | 39.20 (22.4) |
 CD4+ count [mean (sd)] | 418.7 (273.0) | 440.02 (289.1) |
 log10 viral load [mean (sd)] | 3.1 (1.2) | 2.74 (1.2) |
 Antiviral medication adherence (%) | 1117 (77.8%) | 666 (76.1%) |